Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 16/20 | 0.40 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | LIPE | Q05469 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2617862 | 1.00 | AR (0.40) | ARTRPV4FFAR1NR3C1PIK3CD | |
| SCHEMBL2617842 | 0.91 | AR (0.43) | ARTRPV4PIK3CDPIK3CALIPE | |
| SCHEMBL2118248 | 0.91 | AR (0.43) | ARTRPV4PIK3CDPIK3CALIPE | |
| SCHEMBL2617861 | 0.90 | AR (0.41) | ARFFAR1NR3C1PIK3CDPIK3CA | |
| SCHEMBL2118296 | 0.90 | AR (0.41) | ARFFAR1NR3C1PIK3CDPIK3CA | |
| SCHEMBL2617878 | 0.88 | AR (0.44) | AR | |
| SCHEMBL2120256 | 0.88 | AR (0.44) | AR | |
| SCHEMBL2120611 | 0.85 | SIRT6 (0.41) | PIK3CDPIK3CALIPE | |
| SCHEMBL2617857 | 0.85 | SIRT6 (0.41) | PIK3CDPIK3CALIPE | |
| SCHEMBL2119410 | 0.84 | AR (0.46) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507474-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2013-08-13 | — | — | US | disclosed |
| US-8507474-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2013-08-13 | — | — | US | disclosed |
| EP-2443091-B1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INT BV (NL) | 2013-04-03 | — | — | EP | disclosed |
| EP-2443091-A1 | ANTHELMINTIC AGENTS AND THEIR USE | Intervet International B.V. (NL) | 2012-04-25 | — | — | EP | disclosed |
| US-20120094981-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2012-04-19 | — | — | US | disclosed |
| US-20120094981-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2012-04-19 | — | — | US | disclosed |
| WO-2010146083-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094981-A1 | ANTHELMINTIC AGENTS AND THEIR USE | ABCB11, ACHE, CMA1 | AR 4346/4885TRPV4 1112/4885FFAR1 4535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.